These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

780 related items for PubMed ID: 29955867

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 4. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jan; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Jan; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 6. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
    Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I.
    Immunotherapy; 2017 Sep; 9(10):797-804. PubMed ID: 28877632
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 19. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M, Armenti ST, Ayres MB, Demirci H.
    JAMA Ophthalmol; 2018 May 01; 136(5):553-556. PubMed ID: 29677240
    [Abstract] [Full Text] [Related]

  • 20. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J, Kordbacheh T, Larkin J.
    Expert Opin Drug Saf; 2015 Jun 01; 14(6):957-64. PubMed ID: 25927979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.